Treatment Clinical Trial
Official title:
Clinical Study on the Effect of Routine Treatment and Intensive Treatment on the Regulation of Graves' Disease and the Cumulative Recurrence Two Years After Drug Withdrawal
In this study, the dose of methimazole was adjusted according to the different states of thyroid function, and the effects of conventional therapy and intensive therapy on the cumulative recurrence of Graves' hyperthyroidism after two years of drug withdrawal were evaluated. At the same time, the changes of immune indexes and inflammatory factors in the regulation process were evaluated. This study is a phase IV clinical study designed and carried out by the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), which is a randomized, open and routine treatment group with parallel control.
Status | Recruiting |
Enrollment | 240 |
Est. completion date | July 31, 2030 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Graves hyperthyroidism (responsible for doctors' clinical diagnosis) - Age 18-65, for both men and women - Thyroid receptor antibody (TRAb) was positive - Take part in this research voluntarily and sign the informed consent form Exclusion Criteria: - Those who have used glucocorticoid or other immunosuppressants for a long time within 3 months before being selected - Those who have participated in any other drug trials within 3 months before being selected - Subjects who are participating in clinical research of other drugs - Patients with a history of malignant tumors - Ill-controlled hypertension: diastolic blood pressure=100mmHg, systolic blood pressure =160 mmHg - Blood routine: the total number of white blood cells < 3.0×109 or neutrophils < 1.5× 109 - Other thyroid diseases: such as subacute thyroiditis, thyroid nodules, high-function adenoma - Alanine aminotransferase(ALT) or aspartate amino transferase(AST) is greater than 2 times of the normal upper limit; When ALT or AST is less than 2 times of the normal upper limit, and the test of hepatitis B two half-and-half positive - Renal insufficiency: serum creatinine is higher than the upper limit of normal value - Patients with heart failure - Patients with coronary heart disease - Patients with other autoimmune diseases - Patients who are known to be allergic to any component of this medicine are allergic to the active ingredients or any auxiliary materials in the prescription - Patients with multiple drug allergies, allergic diseases, people with high sensitivity and drug addicts - Alcoholism, mental disorder or other observers who are not suitable for drug testing - Pregnant and lactating women cannot rule out the possibility of pregnancy - Taking any medicine with unknown ingredients or using traditional Chinese medicine, the researcher judges the medicine that may affect the curative effect of hyperthyroidism - According to the researcher's judgment, other medical history that reduces the possibility of joining the group or complicates the joining of the group, such as frequent changes in the working environment, may easily lead to lost follow-up. Rejection Criteria: - The compliance of this clinical trial protocol is < 80% or > 120%; - Those who did not meet the inclusion criteria or the exclusion criteria were found during the experiment; - Those who can't cooperate, including those who can't complete the whole course of treatment, don't complete the follow-up as planned, and increase or decrease adjuvant drugs at will; - During the trial, use other drugs that may affect the curative effect of this trial. Termination of Research Criteria: - Those who are allergic or intolerant to this drug; - Adverse reactions or serious adverse events that patients can't tolerate occur; - Pregnant women of childbearing age in the experiment; - Other diseases appear during the treatment, and the treatment of accompanying diseases will interfere with the clinical observers of this medicine; - The researcher thinks it is inappropriate to continue the experiment. |
Country | Name | City | State |
---|---|---|---|
China | the First Affiliated Hospital of Nanjing Medical University | Nanjing |
Lead Sponsor | Collaborator |
---|---|
The First Affiliated Hospital with Nanjing Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cumulative recurrence rate between conventional treatment group and intensive treatment group after two years of withdrawal. | Patients took medicine according to the course of treatment. Relapse occurs when the thyroid function returns to hyperthyroidism within 2 years after the drug is stopped. | Up to 2 years after drug withdrawal | |
Primary | Number of patients with no adverse reactions during the treatment of Graves' disease | The patient completed the methimazole treatment, and there were no adverse reactions that needed to be stopped. Adverse reactions refer to any symptoms, syndromes or diseases that affect patients' health during clinical research and observation, and also include clinically relevant situations found in the laboratory or other diagnostic processes, such as unplanned diagnosis and treatment measures, withdrawal from research, or clinically significant laboratory examination items. Blood routine, liver function, kidney function and adverse reactions will be recorded during the follow-up. | Within the treatment period (average 2 years) | |
Secondary | Cumulative recurrence rate of hyperthyroidism in conventional treatment group and intensive treatment group after stopping treatment for one year. | Patients took medicine according to the course of treatment. Relapse occurs when the thyroid function returns to hyperthyroidism within 1 years after the drug is stopped. | Up to 1 years after drug withdrawal | |
Secondary | Effects of routine treatment and intensive treatment on titer and positive rate of thyroid autoantibodies | Thyroid function and related antibodies were detected every 4 ~ 8 weeks, and the positive rate and titers of thyroid autoantibodies (including TPOAb, TGAb and TRAb) were compared. | During treatment(average 2 years) and within 2 years after drug withdrawal | |
Secondary | Effect of conventional therapy and intensive therapy on thyroid volume | The changes of thyroid volume during treatment and withdrawal were compared. | During treatment(average 2 years) and within 2 years after drug withdrawal | |
Secondary | Effects of conventional therapy and intensive therapy on cytokines | The changes of cytokines before and after different treatments were compared. | During treatment(average 2 years) and within 2 years after drug withdrawal |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05243134 -
The Influence of Anatomic Deformities on the Clinical Efficacy in the Patients With Patellar Dislocation
|
||
Completed |
NCT02486874 -
Clinical Evaluation of PoreSkin
|
Phase 1 | |
Active, not recruiting |
NCT04592640 -
Stem Cells for Uremic Calciphylaxis Patients
|
N/A | |
Recruiting |
NCT04599686 -
Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer
|
N/A | |
Recruiting |
NCT03351842 -
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
|
Phase 2 | |
Completed |
NCT02782442 -
Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM)
|
N/A | |
Completed |
NCT03439930 -
The Effect of Balance Training on Neuromuscular Control in Subjects With CAI
|
N/A | |
Not yet recruiting |
NCT05537155 -
Buccal Acupuncture for Delirium Treatment in Older Patients Recovering From Orthopedic Surgery
|
N/A | |
Recruiting |
NCT02971982 -
PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia
|
Phase 1/Phase 2 | |
Completed |
NCT02820272 -
Water for Reducing Pain in Negative Pressure Wound Therapy
|
Phase 2 | |
Completed |
NCT00984958 -
Bulkamid Treatment of Stress Incontinence in Women With Urinary Stress Incontinence and Not Suitable to TVT-procedure
|
N/A | |
Completed |
NCT00575224 -
Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9
|
Phase 4 | |
Completed |
NCT00164307 -
Assisting Children With Prenatal Alcohol Exposure in Developing Peer Friendships
|
Phase 1/Phase 2 | |
Completed |
NCT00164528 -
Intervening With Children/Adolescents With FAS/ARND
|
Phase 1/Phase 2 | |
Recruiting |
NCT04603586 -
Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses
|
N/A | |
Recruiting |
NCT03375424 -
Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany
|
N/A | |
Not yet recruiting |
NCT04062370 -
Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion
|
Phase 4 | |
Not yet recruiting |
NCT02931136 -
Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging
|
Phase 4 | |
Completed |
NCT04661228 -
Diagnostic Survey of Mental and Substance Use Disorders in HUNT (PsykHUNT)
|
||
Recruiting |
NCT03365141 -
Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo
|
N/A |